Pfizer And Amgen Strike A Deal To Settle US Pegfilgrastim Tussle
Nyvepria Biosimilar Has Been Available For More Than A Year
Pfizer’s Nyvepria biosimilar was the fourth pegfilgrastim biosimilar approved by the FDA, despite ongoing litigation from originator Amgen. The biosimilar sponsor has cleared any niggling legal issues by settling litigation over a US patent directed at methods of protein purification.
